CA3067858A1 - Method for reducing lung infection - Google Patents

Method for reducing lung infection Download PDF

Info

Publication number
CA3067858A1
CA3067858A1 CA3067858A CA3067858A CA3067858A1 CA 3067858 A1 CA3067858 A1 CA 3067858A1 CA 3067858 A CA3067858 A CA 3067858A CA 3067858 A CA3067858 A CA 3067858A CA 3067858 A1 CA3067858 A1 CA 3067858A1
Authority
CA
Canada
Prior art keywords
chelating agent
antibiotic
day
inhaled
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3067858A
Other languages
English (en)
French (fr)
Inventor
Barry Clements
Original Assignee
Respirion Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902364A external-priority patent/AU2017902364A0/en
Application filed by Respirion Pharmaceuticals Pty Ltd filed Critical Respirion Pharmaceuticals Pty Ltd
Publication of CA3067858A1 publication Critical patent/CA3067858A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CA3067858A 2017-06-20 2018-06-20 Method for reducing lung infection Pending CA3067858A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017902364 2017-06-20
AU2017902364A AU2017902364A0 (en) 2017-06-20 Method For Reducing Lung Infection
AU2018900765A AU2018900765A0 (en) 2018-03-08 Method for Reducing Lung Infection
AU2018900765 2018-03-08
PCT/AU2018/050610 WO2018232453A1 (en) 2017-06-20 2018-06-20 Method for reducing lung infection

Publications (1)

Publication Number Publication Date
CA3067858A1 true CA3067858A1 (en) 2018-12-27

Family

ID=64735417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067858A Pending CA3067858A1 (en) 2017-06-20 2018-06-20 Method for reducing lung infection

Country Status (8)

Country Link
US (1) US11382884B2 (https=)
EP (1) EP3641750A4 (https=)
JP (2) JP7389653B2 (https=)
CN (1) CN111065386A (https=)
AU (3) AU2018286650B2 (https=)
BR (1) BR112019027255A2 (https=)
CA (1) CA3067858A1 (https=)
WO (1) WO2018232453A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210361581A1 (en) * 2018-10-22 2021-11-25 Ioi Oleo Gmbh Additive for a powder material intended for compaction into shaped bodies
CN116173037A (zh) * 2023-04-14 2023-05-30 中国人民解放军总医院 咖啡因在预防和/或治疗急性高原病中的应用
US20250108004A1 (en) * 2023-09-29 2025-04-03 Sterilecare Inc. Aerosol delivery of edta compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
WO2011142677A1 (en) * 2010-05-11 2011-11-17 Breathe Easy Ltd Methods and compositions for the treatment of lung disorders
AU2016228976B2 (en) * 2015-03-11 2018-11-08 University Of Cincinnati Compositions and methods for treating bacterial infection

Also Published As

Publication number Publication date
EP3641750A1 (en) 2020-04-29
AU2018286650A1 (en) 2019-12-05
JP2024001036A (ja) 2024-01-09
AU2025256218A1 (en) 2025-11-13
WO2018232453A1 (en) 2018-12-27
BR112019027255A2 (pt) 2020-07-14
CN111065386A (zh) 2020-04-24
EP3641750A4 (en) 2021-03-24
US20200108033A1 (en) 2020-04-09
AU2023285900B2 (en) 2025-11-20
JP2020524172A (ja) 2020-08-13
AU2018286650B2 (en) 2023-09-21
JP7642033B2 (ja) 2025-03-07
AU2023285900A1 (en) 2024-01-18
US11382884B2 (en) 2022-07-12
JP7389653B2 (ja) 2023-11-30

Similar Documents

Publication Publication Date Title
AU2023285900B2 (en) Method For Reducing Lung Infection
US11116765B2 (en) Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
US9968555B2 (en) Liposomal formulations that form drug nanocrystals after freeze-thaw
JP2025098035A (ja) 肺炎症を低減させる方法
CA2461903A1 (en) Monobactam antibacterial compounds and methods of use thereof
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220215

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240715

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B302 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - CONDITIONS FOR GRANT DETERMINED NOT COMPLIANT

Effective date: 20240909

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250715

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260205